Últimas noticias sobre Vaccinex (NASDAQ:VCNX) Bolsa

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Vaccinex Inc

Beam Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.12) by 175 percent. The company reported quarterly sales of $11.482 million which missed the analyst consensus estimate of $18.863 million by 39.13 percent. This is a 30.35 percent decrease over sales of $16.486 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

BEEM

Beam Global Q3 2024 GAAP EPS $0.09 Beats $(0.12) Estimate, Sales $11.482M Miss $18.863M Estimate

Lantmännen will invest more than 100 million euros in a state-of–the-art <a href="https://www.globenewswire.com/Tracker?data=D-7Y-KVbP6QZknfadXEZ-FyiOL801tmcb6MoPLIt1GBtRzzMxYqB5y0WMAfkDOuP8wF9RdBMPWvDS7IIKC_OkWudCUCt9vi-8ARGYU9fdadf5aFadydlfMoC2c0oEek0wq9shl6f0tFxH4iEsBbG2plhHfhgHB7WME97-NbSZIM6dfFRmaj3AkU_gZXrXeRD6wSfFlbL5NZEKQdFWd05Ix8BUt1dMN_MHpAiD0GLnSSve8knOhEkT3alPDLqD0Z4qqemEbKkxRZ3MJ3oKFuKXBYY26VDZ92n-tTgubAPhQo=">factory in Sweden</a>, while partnering with Ingredion to develop a differentiated portfolio of plant-based protein isolates based on yellow peas. Construction of the production plant will be completed in 2027.

INGR

Reported Earlier, Ingredion And Lantmännen Forge Strategic Alliance To Boost European Plant-Based Protein Market, Invest Over €100M In New Pea Protein Facility

Macro Economic Events

Econ #s

Economics

U.K. Trade Balance Non-EU For September -5.31B Vs. -4.85B (Revised) Prior

U.K. Trade Balance For September -16.32B Vs. -15.70B Est.; -15.21B (Revised) Prior

U.K. Monthly Gross Domestic Product (GDP) 3M/3M Change For September 0.1% Vs. 0.2% Est.; 0.2% Prior

U.K. Manufacturing Production (MoM) For September -1.0% Vs. 0.0% Est.; 1.3% (Revised) Prior

U.K. Industrial Production (MoM) For September -0.5% Vs. 0.1% Est.; 0.5% Prior

U.K. Gross Domestic Product (QoQ) Preliminary For Q3 0.1% Vs. 0.2% Est.; 0.5% Prior

U.K. Gross Domestic Product (YoY) Preliminary For Q3 1.0% Vs. 0.1% Est.; 0.7% Prior

U.K. Gross Domestic Product (MoM) For September -0.1% Vs. 0.2% Est.; 0.2% Prior

U.K. Business Investment (QoQ) Preliminary For Q3 1.2% Vs. 0.6% Est.; 1.4% Prior

Billionaire investor David Tepper&#8216;s Appaloosa Management reduced its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) by 5% in the third quarter, despite his recent public enthusiasm for Chinese investments, according to regulatory filings released Thursday.
What Happened: The reduction comes just months after Tepper declared that he <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41050711/stocks-rise-as-china-signals-more-stimulus-billionaire-david-tepper-bets-big-on-everythi">would buy &#8220;everything&#8221; China-related</a> amid Beijing&#8217;s stimulus efforts. Despite the trim, Alibaba remains Appaloosa&#8217;s largest holding, representing 15.75% of its $6.7 billion equity portfolio.
The hedge fund&#8217;s third-quarter moves reveal a complex strategy toward Chinese investments. While reducing positions in the iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>), KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>), and Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), Tepper more than doubled his stake in PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) and increased positions in JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) and KE Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>).
The filing also revealed significant reductions in major U.S. technology holdings. Appaloosa sold 275,000 shares of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), representing an 8.59% reduction while cutting its Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) position by 211,356 shares, or 21.89%. The fund also reduced its stake in Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) by 310,000 shares, a 49.6% decrease, and trimmed its position in Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>).
See Also: <a href="https://www.benzinga.com/news/global/24/11/41998381/tesla-earnings-will-be-hit-hardest-if-7500-ev-credit-is-cut-warns-gary-black-citing-80-dependence-on-ev-sales-please-do-the-math">Tesla Earnings Will Be Hit Hardest If $7.5K EV Credit Gets Cut By Trump, Warns Gary Black: &#8216;Do The Math&#8217;</a>
Why It Matters: Overall, Tepper&#8217;s exposure to Chinese stocks and ETFs increased to 38% of his equity portfolio in the third quarter, up from 26% in the previous quarter. This positions him, alongside Scion Asset Management&#8216;s Michael Burry, as one of the few prominent hedge fund managers <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">maintaining significant Chinese market exposure</a>. 
These portfolio adjustments come as Chinese stocks face headwinds from disappointing fiscal policies and persistent economic challenges, including weak consumer spending and an unstable property market. Market observers note that geopolitical tensions and potential tariff increases add further <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41902202/trumps-china-hawks-rumored-for-top-roles-yuan-hits-3-month-low">uncertainty to the investment landscape</a>.
The details of these transactions were disclosed in a Form 13F filing, a quarterly report required by the Securities and Exchange Commission for institutional investment managers overseeing more than $100 million in qualifying securities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41998258/cathie-wood-keeps-betting-on-amazons-haul-play-ark-loads-up-6m-worth-of-shares">Cathie Wood Keeps Betting On Amazon&#8217;s &#8216;Haul&#8217; Play: Ark Loads Up $6M Worth Of Shares</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Asia

Equities

Markets

ETFs

AMZN

BABA

BEKE

BIDU

GOOG

KWEB

MSFT

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Billionaire David Tepper's China Puzzle: Appaloosa Cuts Alibaba Stake While Doubling Down On PDD

QUBT

Reported Earlier, Quantum Computing Secures $40M Through Registered Direct Offering, Pricing 16M Shares At $2.50 Each in At-the-Market Deal

Michael Saylor, CEO of MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), deemed the Donald Trump-led Republican triumph the &#8220;biggest&#8221; bullish catalyst for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) over the last four years.
What Happened: In an interview with CNBC on Thursday, Saylor said that the &#8220;red wave&#8221; has been &#8220;incredibly auspicious&#8221; for Bitcoin and the broader cryptocurrency industry.
The Bitcoin bull anticipated a friendlier SEC at the helm amid speculations of current chair Gary Gensler stepping aside.
&#8220;It&#8217;s very good for the cryptocurrency industry. We&#8217;re going to see a lot more pro-Bitcoin policies. We are going to see a digital assets framework. We are going to see an end to the war on crypto.,&#8221; Saylor predicted.
Don&#8217;t Miss:
<ul>
<li>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.</a></li>
<li>1 in 4 Americans own a share of Bitcoin according to NASDAQ — <a href="https://www.benzinga.com/money/binance-100">this platform touts returns as high as 12.5% APY and is giving $100 in welcome rewards if you sign up today.</a></li>
</ul>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;The red wave is probably the biggest thing that has happened in the past four years for bitcoin&quot; &#8211; <a href="https://twitter.com/MicroStrategy?ref_src=twsrc%5Etfw">@MicroStrategy</a> founder &amp; chairman <a href="https://twitter.com/saylor?ref_src=twsrc%5Etfw">@saylor</a> on his crypto expectations under a second Trump presidency. <a href="https://t.co/9BYAYgLGe8">pic.twitter.com/9BYAYgLGe8</a>
&mdash; CNBCOvertime (@CNBCOvertime) <a href="https://twitter.com/CNBCOvertime/status/1857179737606459844?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
With the election uncertainty behind, Saylor also ruled out any major bearish events for Bitcoin in the foreseeable future.
&#8220;I am planning the $100,000 party, and I am thinking it is probably going to be New Year&#8217;s Eve at my house. So, I would be surprised if we don&#8217;t go through $100,000 in November or December,&#8221; Saylor said in a burst of enthusiasm.
See Also: Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a>
Why It Matters: Saylor&#8217;s bullish sentiment aligned with the ongoing success of his company&#8217;s publicly-traded stock. 
MicroStrategy&#8217;s shares hit a record high earlier this week, pushing the firm&#8217;s market valuation to $72.26 billion, a $50 billion increase since September 6. This gain <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41961419/bitcoin-proxy-microstrategy-added-more-to-its-market-cap-in-last-2-months-than-what-ford-is-worth-currently">surpassed the total capitalization</a> of Ford Motor Co. (F) and Cognizant Technology Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>).
The firm, known famously as Bitcoin&#8217;s biggest corporate holder, was sitting on unrealized profits of over $12.7 billion as of this writing, <a href="https://bitcointreasuries.net/" target="_blank" rel="noreferrer noopener">according&nbsp;</a>to data from bitcointreasuries.net.&nbsp;&nbsp;
The company&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil" target="_blank" rel="noreferrer noopener">announced plans</a>&nbsp;to raise as much as $42 billion in equity and debt funding over the next three years to accumulate more Bitcoin.
Price Action: At the time of writing, Bitcoin was exchanging hands at $88,121.00, down 1.89% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>. Shares of MicroStrategy closed 0.22% lower at $327.67 during Thursday&#8217;s regular trading session.
Photo Courtesy: Wikimedia
Read Next: 
<ul>
<li>This well known prop trading firm is offering 100% of your first $25,000 profit per account and 90% after that. <a href="https://www.benzinga.com/money/apex-trader-funding">Here's how to get a special 50% OFF CODE that lets you start out with monthly investments as low as $147 today.</a></li>
<li>If you invested $100 in DOGE when Elon Musk first tweeted about it in 2019,<a href="https://www.benzinga.com/money/etoro-doge"> here&#8217;s how much you&#8217;d have today</a>.</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CTSH

MSTR

Michael Saylor Is Planning A Bitcoin $100K Party At His House, Expects End Of War On Crypto Under Trump

AGAE

Reported Earlier, AGAE Responds To Knighted's Legal Claims, Alleging Roy Choi's Attempt To Undermine Board's Strategic Decisions For Short-Term Gains

Elon Musk&#8216;s SpaceX has been increasing its launch cadence, enabling 17 launches in the last 31 days, and exceeding its <a href="https://www.benzinga.com/news/24/01/36860379/one-month-into-2024-spacex-is-already-falling-short-of-its-own-launch-targets-temporary-setback-or-c">monthly launch targets</a>.
What Happened: SpaceX&#8217;s Falcon 9 rocket launched 24 Starlink satellites to low-Earth orbit from Florida on Thursday, marking its 17th launch in 31 days.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Falcon 9 lifts off from pad 40 in Florida, completing our 17th launch in 31 days! <a href="https://t.co/w0snRDcUA9">pic.twitter.com/w0snRDcUA9</a>
&mdash; SpaceX (@SpaceX) <a href="https://twitter.com/SpaceX/status/1857082099154456924?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
SpaceX launched almost every other day in the last 31 days, exceeding its target set at the start of the year of 12 launches every month. 
However, the Musk-led space giant <a href="https://www.benzinga.com/news/24/07/39612042/elon-musks-spacex-launches-67-missions-in-first-half-of-2024-trailing-own-targets">fell short of its launch targets</a> in the first half of 2024, completing just 67 missions, not including its Starship test flights. The company is now trying to reach its launch target for the whole year by amping up launches in the remaining months.
Why It Matters: SpaceX has already exceeded 100 launches this year, outrunning its 96 launches in 2023. 
SpaceX VP of Launch Kiko Dontchev said earlier this month that the company will <a href="https://www.benzinga.com/news/24/11/41767169/spacex-completes-400th-successful-falcon-launch-to-date-but-will-miss-target-of-144-launches-in-2024">not make its goal of 144 launches this year</a> but is still targeting 30 more launches, or one launch every two days, for the rest of the year.
SpaceX is currently using its Falcon launch vehicles for the payload carrying missions. The company is also testing its Starship launch vehicle, whose next test flight is expected <a href="https://www.benzinga.com/general/space/24/11/41871398/spacex-aims-to-launch-starship-once-every-2-weeks-by-late-2025-ceo-elon-musk-says-we-will-be-much-faster">as early as Nov. 18</a>. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/partner/fintech/24/11/41939694/the-power-of-leverage-global-broker-octa-lays-out-the-ins-and-outs-of-this-trading-tool-for-trade">Ford Cuts Capri, Explorer EV Output Due To &#8216;Significantly Lower Than Expected Demand&#8217; After Pausing F-150 Lightning Production</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

Tech

SpaceX Speeds Up Mission Launches With A New One Taking Off Every Other Day Over Last Month As It Races Towards Its 2024 Target

The Share Repurchase is being made pursuant to the Company's existing $50.0 million share repurchase program. On November 14, 2024, the Company announced that its Board of Directors authorized a share repurchase program, beginning on the date thereof and continuing through and including December 31, 2025. After the completion of the Share Repurchase described above, there will be $35.0 million remaining under the Company's share repurchase program.

Kodiak Gas Prices Upsized Offering Of 5.7M Common Shares At $34.50/Share; Proceeds To Selling Stockholder, $15M Buyback To Follow

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled lower on Thursday, with the Dow Jones falling more than 200 points during the session as investors digested recent economic reports.
U.S. initial jobless claims declined by 4,000 from the previous week to 217,000 in the week ending Nov. 9, compared to market estimates of 223,000. U.S. producer prices rose 0.2% month-over-month in October compared to a revised 0.1% gain in September, in line with market expectations.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell around 5.8% on Thursday after recording sharp gains in the recent period. The small-cap benchmark Russell 2000 tumbled over 1% during the session.
Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) shares fell over 2% on Thursday despite reporting better-than-expected results for its first quarter.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, industrials, and healthcare stocks recording the biggest losses on Thursday. However, information technology and energy stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 207 points to 43,750.86 on Thursday. The S&amp;P 500 fell 0.60% to 5,949.17, while the Nasdaq Composite fell 0.64% to close at 19,107.65 during Thursday's session.
Investors are awaiting earnings results from Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Spectrum Brands Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>), and RLX Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 60.3, the index remained in the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 65.8.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Trading Ideas

CSCO

TSLA

Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In 'Greed' Zone

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
<ul>
<li>Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity</li>
<li>More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines</li>
<li>FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade &nbsp;</li>
</ul>

REGN

Dupixent's sBLA Resubmission Accepted By FDA; Phase 3 Data Demonstrate Significant Itch And Hive Reduction For Chronic Urticaria Patients

Wing, a drone business backed by Google-parent Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Apian, a British technology start-up, have launched a drone service for NHS blood sample deliveries in London.
What Happened:&nbsp;This new drone service, operating between Guy's and St Thomas' hospitals, reduces delivery time for blood samples from 30 minutes by van or motorbike to just 2 minutes, <a href="https://www.thetimes.com/article/dbd69ffe-252c-4d79-8f1f-ae9474f5b955">reported</a> The Times.
The drones are used to transport critical samples from patients at risk of bleeding disorders, helping to speed up decisions for surgeries and ensuring quick access to lab analysis.
Alphabet CEO Sundar Pichai took to X, formerly Twitter, and said, "Reducing blood sample delivery from 30 min to 2 min means faster results and quicker care for patients in critical need. Important use case for drone technology."
See Also:&nbsp;<a href="https://www.benzinga.com/tech/24/11/41894509/apples-next-big-bet-think-smaller-says-analyst-there-will-never-be-another-iphone?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple&#8217;s Next Big Bet? Think Smaller, Says Analyst: &#8216;There Will Never Be Another… iPhone&#8217;</a>
Guy's and St Thomas' NHS Foundation Trust have also backed this venture.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Reducing blood sample delivery from 30 min to 2 min (!) means faster results and quicker care for patients in critical need. Important use case for drone technology &#8211; well done to <a href="https://twitter.com/Wing?ref_src=twsrc%5Etfw">@Wing</a> <a href="https://twitter.com/Apianaero?ref_src=twsrc%5Etfw">@apianaero</a> <a href="https://twitter.com/NHSuk?ref_src=twsrc%5Etfw">@NHSuk</a> <a href="https://t.co/BPANo3Gr00">https://t.co/BPANo3Gr00</a>
&mdash; Sundar Pichai (@sundarpichai) <a href="https://twitter.com/sundarpichai/status/1857120784713654611?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters:&nbsp;This initiative comes after Alphabet reported a 15% year-over-year increase in <a href="https://www.benzinga.com/news/earnings/24/10/41611263/alphabet-q3-earnings-highlights-revenue-beat-eps-beat-google-cloud-up-35-momentum-across-the-compan">third-quarter revenue</a>, highlighting the company&#8217;s extraordinary momentum.
The drone project also aligns with Alphabet&#8217;s previous ventures into drone delivery services, such as its partnership with DoorDash in the U.S. to deliver food items.
Apian, which identifies itself as a <a href="https://www.benzinga.com/general/24/04/38088421/doordash-partners-with-googles-wing-for-drone-delivery-pilot-in-the-us-to-fly-food-to-your-front-doo">&#8220;healthcare logistics&#8221; business</a>, aims to become the &#8220;Deliveroo of medical transport&#8221;,&nbsp;creating a platform to match&nbsp;clinicians with urgent transport requests&nbsp;and commercial drone companies.
The company&nbsp;was founded in 2020 by&nbsp;Dr. Christopher Law, Dr. Hammad Jeilani, and&nbsp;Alexander Trewby, formerly of Google&nbsp;Health.
Price Action: As of the latest data, Alphabet's Class A shares declined 0.24% in after-hours trading to $175.15, while Class C shares slipped 0.20% to $177. In the regular session on Thursday, Class A and Class C shares closed at $175.58 and $177.35, respectively, according to<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener"> Benzinga Pro data</a>.
World Economic Forum on Flickr
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/11/41927913/amazon-confirms-vendor-data-breach-affecting-2-8m-employee-contacts-adds-to-growing-list-of-moveit-hack-victims?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Amazon Confirms Vendor Data Breach Affecting 2.8M+ Employee Contacts, Adds To Growing List Of MOVEit Hack Victims</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Health Care

Media

GOOGL

Sundar Pichai Praises Google-Backed Apian Drones For Cutting Blood Sample Delivery Time From 30 To 2 Minutes: 'Quicker Care For Patients In Critical Need'

Vaccinex stock plunges 24% on mixed results for Alzheimer's study

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks this morning are earnings reports, a failed merger deal, delisting updates and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>VSee Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock is rocketing more than 159% as the robot maker <a href="https://www.nasdaq.com/press-release/vsee-health-and-ava-robotics-partner-develop-telepresence-solutions-hospital">plans for telepresence solutions</a> for the inpatient intensive care market.</li>



<li>Adagio Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/adgm-stock-quote/">ADGM</a>) shares are soaring close to 36% following its <a href="https://www.businesswire.com/news/home/20240731222906/en/Adagio-Medical-Announces-the-Closing-of-the-Business-Combination-with-ARYA-IV-Creating-a-Publicly-Traded-Company-Focused-on-the-Innovative-Technologies-for-Treatment-of-Cardiac-Arrhythmias">recent public debut</a>.</li>



<li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is surging over 35% alongside heavy pre-market trading.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) shares are gaining more than 29% on a <a href="https://www.businesswire.com/news/home/20240801299565/en/Exicure-Inc.-Receives-Positive-Listing-Determination-from-Nasdaq">positive listing update</a> from the Nasdaq Capital Market.</li>



<li>Australian Oilseeds (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/">COOT</a>) stock is rising 25% after announcing a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-announces-appointment-new-independent-auditor-2024-08-01">new independent auditor</a>.</li>



<li>Tandem Diabetes Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a>) shares are increasing nearly 25% with the release of its <a href="https://www.nasdaq.com/press-release/tandem-diabetes-care-announces-second-quarter-2024-financial-results-and-increases">Q2 earnings report</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) stock is heading over 23% higher with <a href="https://www.nasdaq.com/press-release/vaccinex-reports-positive-data-signal-ad-phase-1b-2-trial-pepinemab-alzheimers">recent clinical trial news</a>.</li>



<li>AGBA Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/">AGBA</a>) shares are climbing more than 13% without any clear news this morning.</li>



<li>Venus Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/vero-stock-quote/">VERO</a>) stock is jumping over 13% on Friday morning.</li>



<li>Integral Ad Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/ias-stock-quote/">IAS</a>) shares are up 13% with its <a href="https://www.nasdaq.com/press-release/ias-reports-second-quarter-2024-financial-results-2024-08-01">latest earnings news</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is plummeting almost 47% <a href="https://www.pr.com/press-release/917157#:~:text=(Nasdaq%3AGPAK)%20(GPAK,and%20that%20trading%20of%20the">alongside a delisting notice</a>.</li>



<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) shares are diving more than 37% with the <a href="https://www.nasdaq.com/press-release/fresh-vine-wine-inc-and-notes-live-inc-mutually-agree-terminate-merger-agreement-2024">termination of a merger agreement</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) stock is tumbling over 30% as Badcock Home Furniture &amp; More <a href="https://nypost.com/2024/08/01/business/major-furniture-chain-badcock-to-shut-all-its-stores-after-120-years/">shuts down all of its stores</a>.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are taking a more than 24% beating on plans for a <a href="https://www.stocktitan.net/news/GNLN/greenlane-announces-board-s-approval-of-reverse-stock-split-9yehmvs5r4ed.html">reverse stock split</a>.</li>



<li>Procore Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pcor-stock-quote/">PCOR</a>) stock is dropping 22% alongside its <a href="https://www.nasdaq.com/press-release/procore-announces-second-quarter-2024-financial-results-2024-08-01">Q2 earnings report</a>.</li>



<li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) shares are sliding close to 21% on Friday morning.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is falling over 20% after releasing its <a href="https://www.theverge.com/2024/8/1/24210656/intel-is-laying-off-over-10000-employees-and-will-cut-10-billion-in-costs">Q2 earnings report</a>.</li>



<li>Smith Micro Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/smsi-stock-quote/">SMSI</a>) shares are decreasing more than 19% with its <a href="https://seekingalpha.com/article/4709513-smith-micro-software-inc-smsi-q2-2024-earnings-call-transcript">latest earnings report</a>.</li>



<li>GraniteShares 2x Long AMZN Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzz-stock-quote/">AMZZ</a>) stock is slipping over 17%.</li>



<li>Snap (NYSE:<a href="https://investorplace.com/stock-quotes/snap-stock-quote/">SNAP</a>) shares close out our pre-market stock movers down more than 17% <a href="https://www.cnbc.com/2024/08/01/snap-shares-plunge-over-20percent-af.html">on weak guidance</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The latest announcement is out from Vaccinex (VCNX). Vaccinex, Inc. has announced new insights from its SIGNAL-AD Phase 1b/2 trial assessing the pe...

Vaccinex Provides Update on Alzheimer's Treatment Trial

Vaccinex says Alzheimer's candidate buoyed by additional early-stage data

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) just reported results for the second quarter of 2024.<ul><li>Vaccinex reported earnings per share of -$3.10.</li><li>The company reported revenue of $232,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vcnx-stock-earnings-vaccinex-for-q2-of-2024/">VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024

An announcement from Vaccinex ( ($VCNX) ) is now available. Chrystyna Bedrij Stecyk has abruptly resigned as a director of Vaccinex, Inc., effectiv...

Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns

Vaccinex exercises warrants for proceeds of $6.2M

Vaccinex files for secondary stock offering

Vaccinex (VCNX) announced that it will present promising new efficacy and safety data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study ...

Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study

Vaccinex (VCNX) provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. Vacci...

Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab

ADGM

AGBA

AKAN

AMZZ

BIIB

CONN

COOT

ESAIY

ESALF

ESLA

GNLN

GPAK

INTC

PCOR

SMSI

SNAP

TNDM

VCNX

VERO

VINE

VSEE

XCUR

Financing

Press Releases

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease at the Alzheimer's Association International Conference, Philadelphia, July 31, 2024

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

General

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Provides Update on ActivMAb® Platform:  Multiple Project Deals and Presentation at SITC

Comments

Vaccinex

Noticias

Últimas noticias sobre Vaccinex (NASDAQ:VCNX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL